Valneva (NASDAQ:VALN) Shares Gap Down to $13.48

Valneva SE (NASDAQ:VALNGet Rating) shares gapped down prior to trading on Wednesday . The stock had previously closed at $13.48, but opened at $12.40. Valneva shares last traded at $12.40, with a volume of 1 shares traded.

Analysts Set New Price Targets

A number of brokerages recently issued reports on VALN. HC Wainwright decreased their target price on Valneva from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, August 19th. Kepler Capital Markets cut Valneva from a “buy” rating to a “hold” rating in a research report on Thursday, July 28th.

Valneva Stock Performance

The firm has a 50 day moving average price of $18.61 and a two-hundred day moving average price of $24.48. The company has a quick ratio of 0.94, a current ratio of 1.16 and a debt-to-equity ratio of 0.72.

Valneva (NASDAQ:VALNGet Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($2.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.32) by ($1.54). The company had revenue of $76.05 million during the quarter, compared to analyst estimates of $21.26 million. Analysts forecast that Valneva SE will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

A number of large investors have recently bought and sold shares of the business. UBS Group AG acquired a new position in Valneva during the 2nd quarter worth $31,000. Jane Street Group LLC lifted its holdings in Valneva by 85.9% during the 1st quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after buying an additional 7,664 shares in the last quarter. Finally, Bank of America Corp DE acquired a new position in Valneva during the 1st quarter worth $858,000. 16.39% of the stock is currently owned by institutional investors.

About Valneva

(Get Rating)

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2.

Featured Stories

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.